[Vascular endothelial growth factor-C (VEGF-C) and vascular endothelial growth factor-D (VEGF-D) in ovarian carcinomas]. 2006

Barbara Rossochacka-Rostalska, and Iwona Gisterek, and Elzbieta Suder, and Rafał Matkowski, and Jolanta Szelachowska, and Jan Kornafel
Katedra Onkologii i Klinika Onkologii Ginekologicznej Akademii Medycznej we Wrocławiu.

OBJECTIVE The aim of the work was to assess vascular endothelial growth factor VEGF-C and vascular endothelial growth factor VEGF-D expression in ovarian carcinomas. METHODS Clinical records and preserved specimens from 80 patients with ovarian cacinoma who underwent treatment at Lower Silesia Centre of Oncology were examined consecutively. RESULTS Most of analysed patients (n=53) had serous adenocarcinomas at III or IV FIGO stage. The median VEGF-C expression analysed semiquantitively using immunohistochemistry method was 3.84, and in 5% of cases expression of marker was not found. Also median VEGF-D expression was 3.71, and reactivity of this cytokine was not found in 16.25% of cases. There was strong correlation between expression of VEGF-C and VEGF-D. Conversely, there was no significant correlation between VEGF-C and VEGF-D expression and clinicopathological features of ovarian carcinoma. Univariate analysis demonstrated that high expression of cytokines wasn't associated with worse survival rate. CONCLUSIONS This incresistence indicated that studies on angiogenesis in ovarian carcinomas should be continued.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011044 Poland A country in central Europe, east of Germany. The capital is Warsaw. Polish People's Republic,Republic of Poland
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

Barbara Rossochacka-Rostalska, and Iwona Gisterek, and Elzbieta Suder, and Rafał Matkowski, and Jolanta Szelachowska, and Jan Kornafel
December 1997, Cancer letters,
Barbara Rossochacka-Rostalska, and Iwona Gisterek, and Elzbieta Suder, and Rafał Matkowski, and Jolanta Szelachowska, and Jan Kornafel
May 2005, Clinical cancer research : an official journal of the American Association for Cancer Research,
Barbara Rossochacka-Rostalska, and Iwona Gisterek, and Elzbieta Suder, and Rafał Matkowski, and Jolanta Szelachowska, and Jan Kornafel
February 2006, International journal of clinical oncology,
Barbara Rossochacka-Rostalska, and Iwona Gisterek, and Elzbieta Suder, and Rafał Matkowski, and Jolanta Szelachowska, and Jan Kornafel
December 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
Barbara Rossochacka-Rostalska, and Iwona Gisterek, and Elzbieta Suder, and Rafał Matkowski, and Jolanta Szelachowska, and Jan Kornafel
December 2015, International journal of surgical pathology,
Barbara Rossochacka-Rostalska, and Iwona Gisterek, and Elzbieta Suder, and Rafał Matkowski, and Jolanta Szelachowska, and Jan Kornafel
January 2003, European journal of gynaecological oncology,
Barbara Rossochacka-Rostalska, and Iwona Gisterek, and Elzbieta Suder, and Rafał Matkowski, and Jolanta Szelachowska, and Jan Kornafel
September 2001, International journal of cancer,
Barbara Rossochacka-Rostalska, and Iwona Gisterek, and Elzbieta Suder, and Rafał Matkowski, and Jolanta Szelachowska, and Jan Kornafel
January 1999, Endocrine pathology,
Barbara Rossochacka-Rostalska, and Iwona Gisterek, and Elzbieta Suder, and Rafał Matkowski, and Jolanta Szelachowska, and Jan Kornafel
November 2010, Nihon rinsho. Japanese journal of clinical medicine,
Barbara Rossochacka-Rostalska, and Iwona Gisterek, and Elzbieta Suder, and Rafał Matkowski, and Jolanta Szelachowska, and Jan Kornafel
November 1999, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!